Valneva SE announced on June 25, 2025, that all resolutions recommended by the Board of Directors were approved by shareholders at its Annual General Meeting in Lyon, France. Key approvals included the 2024 financial statements and delegations for the Board to increase share capital or issue financial instruments.
Dr. Gerd Zettlmeissl, a vaccine expert and biotech entrepreneur with over 30 years of industry experience, was appointed to the Board for a three-year term. His expertise is expected to strengthen the company's strategic direction in vaccine development.
During the meeting, Valneva's management also confirmed the company's full-year 2025 financial guidance. This outcome signals continued stability in corporate governance and provides investors with clarity on the company's financial expectations for the current fiscal year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.